31 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Lynx Investment Advisory

Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 31 shares of the biopharmaceutical company’s stock, valued at approximately $33,000.

Other institutional investors also recently modified their holdings of the company. Prime Capital Investment Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 35.5% in the 4th quarter. Prime Capital Investment Advisors LLC now owns 851 shares of the biopharmaceutical company’s stock valued at $747,000 after purchasing an additional 223 shares during the last quarter. Meeder Advisory Services Inc. boosted its position in shares of Regeneron Pharmaceuticals by 3.4% during the 4th quarter. Meeder Advisory Services Inc. now owns 1,265 shares of the biopharmaceutical company’s stock valued at $1,111,000 after purchasing an additional 42 shares in the last quarter. Bleakley Financial Group LLC grew its stake in Regeneron Pharmaceuticals by 10.6% during the fourth quarter. Bleakley Financial Group LLC now owns 8,977 shares of the biopharmaceutical company’s stock worth $7,884,000 after purchasing an additional 860 shares during the period. Valley National Advisers Inc. increased its holdings in Regeneron Pharmaceuticals by 1.8% in the fourth quarter. Valley National Advisers Inc. now owns 1,394 shares of the biopharmaceutical company’s stock worth $1,224,000 after purchasing an additional 24 shares in the last quarter. Finally, Strategic Blueprint LLC increased its holdings in Regeneron Pharmaceuticals by 2.2% in the fourth quarter. Strategic Blueprint LLC now owns 5,032 shares of the biopharmaceutical company’s stock worth $4,420,000 after purchasing an additional 106 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded up $3.71 on Wednesday, reaching $1,069.90. 183,744 shares of the company’s stock were exchanged, compared to its average volume of 469,431. The stock has a fifty day simple moving average of $1,047.01 and a 200-day simple moving average of $985.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,115.00. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.96 and a quick ratio of 4.51. The firm has a market cap of $117.89 billion, a price-to-earnings ratio of 31.63, a P/E/G ratio of 2.32 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the company earned $8.79 earnings per share. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.45 earnings per share for the current year.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the transaction, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares in the company, valued at approximately $18,941,329.68. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total transaction of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The disclosure for this sale can be found here. Insiders have sold a total of 65,074 shares of company stock worth $64,546,123 over the last ninety days. Company insiders own 7.48% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on REGN. Truist Financial reiterated a “buy” rating and set a $1,200.00 price objective (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 2nd. Wells Fargo & Company boosted their price objective on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Argus lifted their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They set an “outperform” rating and a $1,150.00 price objective on the stock. Finally, Royal Bank of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $1,232.00 to $1,240.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,097.05.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.